Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05485155 · ClinicalTrials.gov registry record · Phase 2
Zemaira Eosinophilic Esophagitis Pilot Study
A Phase 2 study of Eosinophilic Esophagitis, sponsored by Children's Hospital Medical Center, Cincinnati.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 2
- Study locations
NCT05485155: Recruiting Phase 2 study of Eosinophilic Esophagitis, sponsored by Children's Hospital Medical Center, Cincinnati.
NCT05485155 is a Phase 2 study of Eosinophilic Esophagitis that is actively recruiting participants, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 15 participants, below the 864-participant average among 44 other Eosinophilic Esophagitis trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05485155, a Phase 2 study of Eosinophilic Esophagitis, is actively recruiting participants, sponsored by Children's Hospital Medical Center, Cincinnati.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a prospective, open-label drug study that will examine the effects of Zemaira (alpha-1 trypsin inhibitor) in patients with Eosinophilic Esophagitis.
Primary Outcome
Absolute change from baseline A1AT esophageal concentration in participants receiving Zemaira to 24 hours after the last infusion at 4 weeks
Conditions Studied
Interventions
- DRUG Alpha-proteinase inhibitor
Study Locations (2)
Maryland
- The National Institutes of Health - Bethesda
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2025-05-15 |
| Est. Completion | 2027-01 |
| Phase | Phase 2 |
What NCT05485155 shows while recruiting
NCT05485155 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 864-participant average among 44 other Eosinophilic Esophagitis trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Eosinophilic Esophagitis appearing as the primary indexed condition, and to 1 intervention - of which Alpha-proteinase inhibitor is the first listed.
NCT05485155 reports a single indexed study location in Maryland, Ohio.
Frequently Asked Questions
What is clinical trial NCT05485155 about?
NCT05485155 is a clinical study titled "Zemaira Eosinophilic Esophagitis Pilot Study". This is a prospective, open-label drug study that will examine the effects of Zemaira (alpha-1 trypsin inhibitor) in patients with Eosinophilic Esophagitis.
What is the current status of trial NCT05485155?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2025-05-15. Estimated completion is 2027-01.
What conditions does trial NCT05485155 study?
This clinical trial studies the following conditions: Eosinophilic Esophagitis.
What interventions are being tested in trial NCT05485155?
The interventions under investigation include: Alpha-proteinase inhibitor (DRUG).
Who is sponsoring clinical trial NCT05485155?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05485155 being conducted?
This trial has 2 study locations across Maryland, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Eosinophilic Esophagitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05485155's enrollment target sits among peer trials
15 42nd of 44 higher than 3 of 44 other Eosinophilic Esophagitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Eosinophilic Esophagitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks
RECRUITING · Phase 2
-
Dupilumab Versus Topical Corticosteroid Effectiveness - Comparison in the Treatment of Stenotic EoE
RECRUITING · Phase 2
-
Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years
COMPLETED · Phase 2
-
A Study of Flovent in Patients With Eosinophilic Esophagitis
COMPLETED · Phase 2
-
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
COMPLETED · Phase 2
-
Efficacy and Safety of QAX576 in Patients With Eosinophilic Esophagitis
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI